Wells Fargo & Company Reiterates “Equal Weight” Rating for Integer (NYSE:ITGR)

Integer (NYSE:ITGR)‘s stock had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company in a research note issued on Friday, Marketbeat.com reports.

A number of other brokerages have also recently commented on ITGR. Citigroup cut shares of Integer from a “buy” rating to a “neutral” rating in a research note on Thursday. Wall Street Zen upgraded shares of Integer from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. KeyCorp dropped their price target on shares of Integer from $145.00 to $133.00 and set an “overweight” rating on the stock in a research note on Tuesday. Raymond James Financial reduced their target price on Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a report on Friday, July 25th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Integer in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $129.50.

Integer Stock Performance

ITGR traded down $1.77 during midday trading on Friday, reaching $72.12. The company had a trading volume of 472,154 shares, compared to its average volume of 530,672. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. The stock has a market cap of $2.53 billion, a PE ratio of 31.85, a P/E/G ratio of 0.86 and a beta of 0.97. Integer has a 12-month low of $66.50 and a 12-month high of $146.36. The business has a 50-day moving average price of $104.29 and a two-hundred day moving average price of $112.67.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 23rd. The medical equipment provider reported $1.79 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.11. The firm had revenue of $467.69 million for the quarter, compared to analysts’ expectations of $466.45 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.43 earnings per share. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, sell-side analysts expect that Integer will post 6.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integer

Several institutional investors and hedge funds have recently made changes to their positions in ITGR. Salomon & Ludwin LLC bought a new position in shares of Integer during the 3rd quarter valued at $26,000. Global Retirement Partners LLC boosted its position in Integer by 293.8% during the 3rd quarter. Global Retirement Partners LLC now owns 319 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 238 shares during the period. Bessemer Group Inc. boosted its position in Integer by 73.1% during the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 125 shares during the period. SVB Wealth LLC purchased a new stake in Integer during the 1st quarter valued at $35,000. Finally, CWM LLC boosted its position in Integer by 46.1% during the 2nd quarter. CWM LLC now owns 355 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 112 shares during the period. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.